Listing & Compliance Notices

IMAC Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

““Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1) (the “Equity Rule”), and on July 17, 2024, the Company was notified by Nasdaq that it regained compliance with the minimum stockholders’ equity requirement and was subjected to a one-year “Panel Monitor” as defined by Nasdaq Listing Rule 5815(d)(4)(B). On January 21, 2025, the Company rec”

Tilray Brands, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“March 25, 2025, Tilray Brands, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the def”

Dermata Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 25, 2025, Dermata Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Capital Market (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million. In the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, the Company reported stockholders’ equity of approximately $1.6 million, which is below the required minimum.”

Metal Sky Star Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5450(b)).

“March 24, 2025, Metal Sky Star Acquisition Corporation (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5450(b) because the Company has not maintained a minimum 1,100,000 publicly held shares. The Notice has no immediate effect on the listing or trading of the Company’s listed securities (the “Listed Securities”). The Company has 45 calendar days to submit a plan to regain compliance. If the plan is accepted, Nasdaq will grant an exte”

Vestand Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“ions Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has scheduled the Company’s securities for delisting from The Nasdaq Capital Market. This Letter was sent pursuant to an earlier notification letter warning the Company that it was out of compliance with Listing Rule 5550(b)(1), which requires that the Company maintain stockholders’ equity of at least $2,500,000 for continued listing, or to meet the alternatives of market value of listed securities or net income from continuing operations. The Company was provided an opportunity to provide Nasdaq with a specific”

Vestand Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 18, 2025, the Company received a notification letter (the “Letter”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has scheduled the Company’s securities for delisting from The Nasdaq Capital Market. This Letter was sent pursuant to an earlier notification letter warning the Company that it was out of compliance with Listing Rule 5550(b)(1), which requires that the Company maintain stockholders’ equity of at least $2,500,000 for continued listing, or to meet the alternatives of market value of listed securities or n”

Damon Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).

“March 20, 2025, the Company received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from February 3, 2025 to March 19, 2025, the Company’s Market Value of Publicly Held Shares (“MVPHS”) had not maintained a minimum aggregate market value of $15,000,000 required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Rule”). The Notice does not impact the listing of the Common Shares on The Nasdaq”

Urgent.ly Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(b)(3)).

“March 19, 2025, Urgent.ly Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its net income from continuing operations had fallen below the minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(3) (the “Minimum Net Income Requirement”). The Notice also noted that the Company does not meet the alternatives of market value of listed securities or stockholders’ equity (collectively with the Minimum Net Income Requirement”

Stardust Power Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 19, 2025, Stardust Power Inc. (“ Stardust ”) received deficiency letters (each a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying Stardust that: ● for the last 30 consecutive business days, the minimum Market Value of Publicly Held Shares, as defined by Nasdaq (“ MVPHS ”), of Stardust’s common stock has been below the minimum $15 million requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(b)(2)(C) (the “ Minimum Market Value of Publicly Held Shar”

Stardust Power Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“March 18, 2025, notified Stardust of the MVPHS deficiency, and the Notice Dated March 19, 2025, notified stardust of the Minimum Bid Requirement deficiency. These Notices have no immediate effect on the listing of Stardust’s common stock. In accordance with Nasdaq Listing Rules 5810(c)(3)(D), Stardust has 180 calendar days, or until September 15, 2025, to regain compliance with the Minimum Market Value of Publicly Held Share Requirement by maintaining $15 million or more market value of publicly held shares for a minimum of ten consecutive business days during this period. In accordance with N”

Goldenstone Acquisition Ltd. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“March 19, 2025, Goldenstone Acquisition Limited (the “Company”) received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that as the Company had not completed an initial business combination within 36 months of the effective date of its registration statement in connection with its initial public offering, it was not in compliance with Nasdaq IM 5101-2 and was therefore subject to delisting. The Company has until March 26, 2025 to request a hearing before the Nasdaq Hearings Panel (the “Panel”). If the Company does not request”

WW INTERNATIONAL, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 19, 2025, WW International, Inc. (the “Company”) received a written notice from the Nasdaq Listing Qualifications Department (the “Nasdaq Letter”), notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires the Company to maintain a minimum closing bid price of at least $1.00 per share for continued listing on The Nasdaq Global Select Market (the “Minimum Bid Requirement”). The Company’s failure to comply with the Minimum Bid Requirement was based on the Company’s common stock per share price being below the $1.00 threshold for a perio”

Q/C TECHNOLOGIES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 17, 2025, TNF Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the 30 consecutive business days between January 30, 2025, to March 14, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with”

ORION ENERGY SYSTEMS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 20, 2025, the Company received a letter (the “Letter”) from the Staff notifying the Company that it is eligible for an additional 180 calendar day period from the date of the Letter, or until September 15, 2025 (the “Additional Compliance Period”) to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the The Nasdaq Capital Market with the exception of the Bid Price Rule, and the Company’s written notice of”

Vivakor, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 18, 2025, the Company received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company can regain compliance with the minimum bid price requirement at any time within the 180 calendar day period following receipt of the Nasdaq notice, or until Septembe”

HeartSciences Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 19, 2025, HeartSciences Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its quarterly report for the period ended January 31, 2025, the Company reported stockholders’ equity of $1,786,689, and, as of March 19, 2025, the Company did not meet the alternatives of market value of listed s”

LogicMark, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 20, 2025, LogicMark, Inc., a Nevada corporation (the “Company”, “we”, “us” or “our”), received a written notification (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with its Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) because the Company’s closing bid price for its common stock, par value $0.0001 per share (the “Common Stock”), had closed below $1.00 per share for the prior thirty (30) consecutive business days. Pursuant to the Notice, normally a Nasdaq-l”

GD Culture Group Ltd received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 20, 2025, GD Culture Group Limited (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that the Company no longer complies with Nasdaq Listing Rules (the “Rules”). Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing, and the Company’s Form 10-K for fiscal year ended December 31, 2024 reported stockholders’ equity of $2,643. In accordance with the Rules, the Company has 45 calendar days”

BioXcel Therapeutics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“March 20, 2025, the Company received another letter from the Staff stating that, as a result of the Company’s continued non-compliance with the MVLS Requirement, its securities would be delisted from Nasdaq unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to make timely request for a hearing before the Panel to appeal the Staff’s determination. The Company’s request for a hearing will stay any further action by the Staff pending the ultimate outcome of the hearing. The Company’s common sto”

Breeze Holdings Acquisition Corp. received a otc deficiency notice notice regarding other.

“March 17, 2025, the Company received a notice from OTCQX Market stating that the Company is not in compliance with Section 2 of the Requirements for Continued Qualification of the OTCQX Rules for U.S. Companies (the “OTCQX Rules”). Specifically, the notice referenced a deficiency with respect to the Company’s rights and warrants, trading under the tickers “BRZHR” and “BRZHW” respectively, under Section 1.1(A) of the OTCQX Eligibility Criteria, which requires compliance with certain penny stock exemption requirements. The Original Filing incorrectly referenced the Company’s common stock and war”

Distoken Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5450(b)(2)(B)).

“March 19, 2025, Distoken Acquisition Corporation (the “ Company ”) received a deficiency letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(b)(2)(B) since the Company did not maintain 1,100,000 publicly held shares as required under the continued listing standards of The Nasdaq Global Market (the “ Public Shares Requirement ”). The notification received has no immediate effect on the Company’s Nasdaq listing. The Nasdaq rules provide the Company 45 calendar d”

DBX ETF TRUST received a other deficiency notice notice regarding other.

“March 13, 2025, the staff of the Listing Qualifications Department (the “Staff”) of the Cboe BZX Exchange, Inc. (the “Exchange”) provided written notice (the “Deficiency Notification”) to DBX ETF Trust (the “Trust”) that, based on the Staff’s review of the period between November 22, 2024, and January 24, 2025 (the “Review Period”), it had determined that Xtrackers USD High Yield BB-B ex Financials ETF (the “Fund”) did not meet the beneficial holders requirement set forth in Exchange Rule 14.11(l)(4)(B)(i)(c) (the “Rule”), which states that the Exchange will consider the suspension of trading”

Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

“March 18, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the bid price for the Company’s common stock (the “ Common Stock ”), for the last 10 consecutive business days, had closed below $0.10 per share and, as a result, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Na”

Ocean Biomedical, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2)).

“March 14, 2025, the Company received a notice from Nasdaq that Staff has determined that as of March 13, 2025, the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). Accordingly, this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market 1 . Nasdaq Hearings Panel (the “Panel”) will consider this matter in their decision regarding the Company’s continued listing on”

Bowen Acquisition Corp received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A)).

“March 19, 2025, Bowen Acquisition Corp (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, for the prior 30 consecutive business days (through March 18, 2025), the closing market value of listed securities (MVLS) of the Company’s ordinary shares, $0.00001 par value per share (“Ordinary Shares”), had been below the minimum of $50 million required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A). The notice stated that the Company would be afforded 180 calendar days (until Se”

DarioHealth Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 18, 2025, the Company received a letter (the “Letter”), from the Staff approving an extension of an additional 180 calendar days from the date of the Letter, or until September 15, 2025 (the “Additional Compliance Period”) to regain compliance with the Minimum Bid Price Requirement. The Company’s Common Stock will continue to trade under the symbol “DRIO.” If at any time during the Additional Compliance Period, the bid price of the Common Stock closes at or above $1.00 per share for a minimum of ten (10) consecutive trading days, Nasdaq will provide the Company with written confirmation”

Elevation Oncology, Inc. received a nasdaq extension granted notice regarding minimum bid price.

“March 19, 2025, the Nasdaq Listing Qualifications department approved the Company’s request to transfer the listing of the Company’s shares of common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will take effect at the opening of business on March 21, 2025. The transfer of the Company’s listing to The Nasdaq Capital Market is not expected to have any immediate effect on trading in shares of the Company’s common stock. The Company’s shares will continue to trade uninterruptedly under the symbol “ELEV.” The Nasdaq Capital Market operates in substantially”

Breeze Holdings Acquisition Corp. received a otc noncompliance notice notice regarding other.

“March 17, 2025, Breeze Holdings Acquisition Corp. (the “Company”) received a notice from the Issuer Compliance Department of the OTC Markets Group stating that the Company is no longer in compliance with Section 2 of the Requirements for Continued Qualification of the OTCQX Rules for U.S. Companies, which requires compliance with Section 1.1(A) of the OTCQX Eligibility Criteria, requiring the Company to have (1) net tangible assets of $2,000,000, if the Company has been in continuous operation for at least three years, or $5,000,000, if the Company has been in continuous operation for less tha”

LanzaTech Global, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 13, 2025, LanzaTech Global, Inc. (the “Company”) received written notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying it that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the $1.00 per share minimum closing bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notice has no immediate effect on the Company’s Nasdaq listing and its common stock will continue to be listed and”

374Water Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(a)(2)).

“March 13, 2025, 374Water Inc. (the “Company”) notified the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer complies with Nasdaq’s independent director requirement as set forth in Nasdaq Listing Rule 5605(b)(1), which requires a majority of the Company’s Board of Directors (the “Board”) to be comprised of Independent Directors as defined in Nasdaq Listing Rule 5605(a)(2). On that same date, the Company received a letter from Nasdaq confirming the foregoing (the “Letter”). Consistent with Nasdaq Listing Rule 5605(b)(1)(A”

SPAR Group, Inc. received a nasdaq noncompliance notice notice regarding other (rules 5620, 5620(a)).

“January 3, 2025 (the " Nasdaq Noncompliance Letter "), stating that SGRP no longer complies with Nasdaq Listing Rule 5620. Nasdaq Listing Rule 5620(a) requires that a listed company hold an annual meeting of shareholders (the " Annual Meeting Rule "). In the Nasdaq Noncompliance Letter, Nasdaq said that SGRP had 45 calendar days to submit a plan to Nasdaq to regain compliance with the Annual Meeting Rule (the " Compliance Plan "). If Nasdaq in its discretion accepts SGRP's Compliance Plan, Nasdaq can grant an exception of up to 180 calendar days from the fiscal year end, or until June 30, 2025”

Unity Biotechnology, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5450(b)(2), 5450(b)(3)).

“March 14, 2025, UNITY Biotechnology, Inc. (“Unity” or the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that its stockholders’ equity as reported in its Annual Report on Form 10-K had fallen below the minimum stockholders’ equity requirement of at least $10,000,000 for continued listing on The Nasdaq Global Select Market set forth in Nasdaq Listing Rule 5450(b)(1)(A). The letter further indicated that, as of the date of the letter, the Company did not comply with certain requirements under the alternative standards set forth in Nasdaq Listing Rules”

CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“f The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Closing Bid Price Deficiency Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company’s shares of common stock on The Nasdaq Capital Market. The Company has 180 days, or until September 8, 2025, to regain”

AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 17, 2025, The Nasdaq Stock Market LLC (“Nasdaq”) notified Avenue Therapeutics, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s common stock will be suspended at the open of trading on March 19, 2025. As previously reported, the Company was in violation of Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. Also as previously reported, on November 26, 2024, the Company received a delist let”

KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“September 12, 2024, FibroGen received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying FibroGen that for 30 consecutive business days the bid price of FibroGen’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1) (the “Rule”). Therefore, in accordance with the Nasdaq listing rules, FibroGen was provided 180 calendar days, or until March 11, 2025 to regain compliance with the minimum bid price rule. On March 12, 2025, FibroGen received written noti”

Greenwave Technology Solutions, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(a)(3)(A)).

“September 13, 2024, the Company received written notice (the “Notice”) from The Nasdaq Listing Qualification Department (“Nasdaq”) notifying the Company that it was not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”), as the closing bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days. The Notice indicated that the Company has 180 calendar days, or until March 12, 2025, to regain compliance with the Mi”

IMAC Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 13, 2025, the Company received written notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the minimum bid price for its common stock has been below $1.00 per share for 30 consecutive trading days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Pri”

Sharps Technology Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“March 12, 2025, Sharps Technology, Inc. (the “ Company ”), was notified by the staff (the “ Staff ”) of The Nasdaq Stock Market, LLC (“ Nasdaq ”) that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market as the bid price of its securities had closed at less than $1.00 per share over the previous 30 consecutive business days. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), th”

American Bitcoin Corp. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“March 13, 2025, the Company received a further notice from the Staff, notifying the Company that its failure to regain compliance with the MVLS Rule serves as a basis for delisting the Company’s securities from The Nasdaq Capital Market. As previously disclosed, the Company is currently noncompliant with certain other continued listing requirements of The Nasdaq Capital Market. The Company will present a compliance plan to a Nasdaq Hearing Panel (the “Panel”) on April 15, 2025 (the “Hearing”). The Company will seek approval for an extension to execute and demonstrate compliance. The Company’s”

Bannix Acquisition Corp. received a nasdaq delisting notice notice regarding other.

“March 13, 2025, Bannix Acquisition Corp. (the “Company”) received a letter from the Nasdaq Hearings Panel notifying the Company that it will be suspended from trading on The Nasdaq Capital Market (“Nasdaq”) due to the Company’s inability to satisfy the terms outlined in the Nasdaq Hearings Panel’s December 2, 2024 decision. As a result, it is expected that trading in the Company’s securities will move to the OTCQB Venture Market at the open of trading on March 17, 2025, under the current trading symbols of BNIX, BNIXR and BNIXW. The Company intends to provide further updates as appropriate SIG”

OneMedNet Corp received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 12, 2025, OneMedNet Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 31 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). The Staff also noted that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed”

OneMedNet Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“March 12, 2025, OneMedNet Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 31 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). The Staff also noted that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed”

DIH HOLDING US, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(C)).

“March 11, 2025, DIH Holding US, Inc. (the “ Company ”), received a letter (the “Notice”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the closing bid price of the Company’s securities (the “ Bid Price ”) was less than $1.00 per share, which does not meet the requirement for continued listing on The Nasdaq Global Market, as required by Nasdaq Listing Rule 5450(a0(1) (the “ Bid Price Rule ”). In accordance with Nasdaq Listing Rule 5810(c)”

Global Star Acquisition Inc. received a nasdaq delisting notice notice regarding shareholders (rules 5450(a)(2), 5450(b)(2)(A)).

“March 12, 2025, the Company received written notification (the “Delisting Notice”) from Nasdaq that trading in the Company’s securities will be suspended at the open of trading on March 14, 2025. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered for”

ALTISOURCE PORTFOLIO SOLUTIONS S.A. received a nasdaq compliance regained notice regarding market value (rules 5450(b)(3)(C)).

“March 12, 2025, the Company received a notice from Nasdaq stating that since the Company’s MVPHS has been $15 million or greater for the ten-day period of February 19, 2025 to March 11, 2025, the Company has regained compliance with the MVPHS Rule and Nasdaq considers the matter closed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 14, 2025 Altisource Portfolio Solutions S.A. By: /s/ Name: Michelle D. Esterman Title: Chief Financial Off”

Allakos Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“March 12, 2025, Allakos Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between January 27, 2025, through March 11, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a compliance period”

Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“September 10, 2024, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with Nasdaq Rule 5550(b)(1), the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq (the “Minimum Equity Requirement”). In response to the Notice, the Company submitted its plan of regain compliance to Nasdaq (the “Plan”) and on November 26, 2024, the Company received notice from Nasdaq that it had accepted the Plan. In accordance with the Plan, the Company is required to complete a”

ConnectM Technology Solutions, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).

“March 7, 2025, the Company received another notice (the “ Additional Notice ”) from Nasdaq stating that the Company had not regained compliance with the Rule. Accordingly, its securities will be delisted from The Nasdaq Global Market. Unless the Company requests an appeal of the determination before the Nasdaq Hearings Panel (the “ Panel ”) by March 14, 2025, trading of the Company’s common stock will be suspended at the opening of business on March 18, 2025, and a Form 25-NSE will be filed with the Commission, which will remove the Company’s securities from listing and registration on Nasdaq.”

Aditxt, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“March 7, 2025, the Company was notified by the Listing Qualifications Staff (the “Staff”) of Nasdaq that it has determined that as of March 6, 2025, the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days. As a result, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)A)(iii) and the Staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to submit an appeal to Nasdaq on March 14, 2025, which will stay the delisting and suspension of the Company’s securities pending t”

AEye, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 11, 2025, AEye, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the Company has not been in compliance with the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notice has no immediate effect on the Company’s Nasdaq listing and its common stock will continue to be listed under the symbol “LIDR.” In accordance with Listing Rule 5810(c)(3)(A), the Company has a period”